Clinical Trials
66 trialsNCT00640978 2025-05-01
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT01032070 2024-12-12
PETEY
Astellas Pharma Inc
Phase 2 Terminated
NCT01247922 2024-12-06
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Astellas Pharma Inc
Phase 2 Terminated
NCT00750698 2023-07-06
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
Syndax Pharmaceuticals
Phase 2 Terminated
NCT00597597 2023-05-17
Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer
Rush University Medical Center
Phase 2 Terminated
NCT00570258 2021-03-30
Randomized, Double Blind Multicenter Phase II Study of Time to Progression on Fulvestrant in Combination With Erlotinib or Placebo in Hormone Receptor-Positive Metastatic Breast Cancer (MBC) Subjects Who Progressed on First Line Hormonal Therapy
University of Arkansas
Phase 2 Terminated
NCT02714530 2021-03-30
ThoRaT
Oslo University Hospital
Phase 2 Terminated
NCT00760929 2021-01-05
A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).
Hoffmann-La Roche
Phase 2 Terminated
NCT02318368 2020-10-22
FOCAL
AVEO Pharmaceuticals, Inc.
Phase 2 Terminated
NCT00843531 2020-09-29
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
University of California, San Francisco
Phase 2 Terminated
NCT01038856 2020-08-24
OSI-TAR-766
University of Oklahoma
Phase 2 Terminated
NCT01857271 2020-07-08
EVENT
Albert Einstein College of Medicine
Phase 2 Terminated
NCT02169284 2020-07-07
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01192815 2020-05-12
Erlotinib Hydrochloride and Radiation Therapy in Stage III-IV Squamous Cell Cancer of the Head and Neck
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00539617 2020-03-23
Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery
University of California, San Francisco
Phase 2 Terminated
NCT02117024 2020-02-05
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Heat Biologics
Phase 2 Terminated
NCT02770014 2019-11-22
Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01182350 2019-09-04
Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT01822496 2019-08-05
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Terminated
NCT02556593 2019-04-12
IMRT Combined With Erlotinib for EGFR Wild Type Non-small Cell Lung Cancer With 4-10 Brain Metastases
Sun Yat-sen University
Phase 2 Terminated
NCT01518621 2019-03-13
RadEr
Oslo University Hospital
Phase 2 Terminated
NCT00750555 2019-02-26
Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer
Geisinger Clinic
Phase 2 Terminated
NCT01962896 2019-02-26
A Phase II Study of Sirolimus and Erlotinib in Recurrent/Refractory Germ Cell Tumors
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT01376310 2019-02-19
GSK1120212 Rollover Study
Novartis
Phase 2 Terminated
NCT00276744 2018-10-24
Individualized Drug Treatment for Treating Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00832637 2018-06-29
Gem-ox
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00281021 2018-03-29
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
University of Louisville
Phase 2 Terminated
NCT01531712 2017-08-29
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
Institut Català d'Oncologia
Phase 2 Terminated
NCT00592007 2017-06-06
Study Evaluating the Addition of Fulvestrant to Erlotinib in Stage IIIB/IV Non-Small Cell Lung Cancer
University of California, San Diego
Phase 2 Terminated
NCT00841035 2017-05-19
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
University of Alabama at Birmingham
Phase 2 Terminated
NCT00392665 2017-04-13
Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck
Massachusetts General Hospital
Phase 2 Terminated
NCT01059305 2017-04-04
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00947167 2017-03-03
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Stanford University
Phase 2 Terminated
NCT01108458 2017-03-03
A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma
Stanford University
Phase 2 Terminated
NCT02095782 2017-03-03
INNOVATE
Guangdong Association of Clinical Trials
Phase 2 Terminated
NCT00470535 2017-02-23
Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT00336700 2016-09-19
A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer
University of Pittsburgh
Phase 2 Terminated
NCT01003938 2016-06-30
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
NYU Langone Health
Phase 2 Terminated
NCT00766636 2016-05-19
Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00063258 2016-05-09
Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00532441 2016-02-12
Erlotinib in Combination With Docetaxel in Advanced Hepatocellular and Biliary Tract Carcinomas
Hoosier Cancer Research Network
Phase 2 Terminated
NCT00988169 2015-11-20
Erlotinib and AT-101 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT01189435 2015-11-18
Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib
Memorial Sloan Kettering Cancer Center
Phase 2 Terminated
NCT00749567 2015-09-28
Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer
Hellenic Oncology Research Group
Phase 2 Terminated
NCT00391586 2015-08-17
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT01009203 2015-08-10
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00442507 2015-07-24
OSI3650
Washington University School of Medicine
Phase 2 Terminated
NCT00459901 2015-04-29
Study of the Antitumor Activity of Capecitabine in Combination With Erlotinib in Patients With Metastatic Colorectal Cancer
Beth Israel Medical Center
Phase 2 Terminated
NCT00940875 2015-04-02
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 2 Terminated
NCT00452075 2014-12-11
Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
Rigshospitalet, Denmark
Phase 2 Terminated